MedTrace Logo

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

NCT04045730 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-01-09

No results posted yet for this study

Summary

This is an open-label single arm phase 2 study for patients with metastatic pancreatic ductal adenocarcinoma who have not received any prior systemic therapies.

Conditions

  • Pancreas Adenocarcinoma

Interventions

DRUG

Gemcitabine

All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Michael Cecchin, MD · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2019-12-31
Completion
2021-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04045730 on ClinicalTrials.gov